# Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 17 | 9.5 | 178.5 | (103.9-285.8) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 11.1 | 72.0 | (31.0-141.9) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 1.5 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 5.1 | nc | (nc-nc) |  | Male | 28 | 37.2 | 75.3 | (50.0-108.8) |
| Female | 3 | 4.3 | nc | (nc-nc) |  | Female | 38 | 30.8 | 123.3 | (87.2-169.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

163

# Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 28 | 44.1 | 63.5 | (42.2-91.7) |  | Male | 30 | 26.8 | 112.1 | (75.6-160.0) |
| Female | 8 | 15.9 | 50.3 | (21.7-99.2) |  | Female | 24 | 20.2 | 118.7 | (76.1-176.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 7.2 | 124.5 | (56.8-236.4) |  | Male | 8 | 8.1 | 99.1 | (42.7-195.3) |
| Female | 5 | 6.3 | 78.9 | (25.4-184.2) |  | Female | 7 | 6.7 | 105.2 | (42.1-216.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 21 | 23.7 | 88.6 | (54.8-135.4) |
| Female | 175 | 160.2 | 109.2 | (93.6-126.7) |  | Female | 23 | 20.4 | 112.6 | (71.3-168.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 18.2 | 71.2 | (37.9-121.8) |
| Female | 2 | 5.1 | nc | (nc-nc) |  | Female | 7 | 8.4 | 83.2 | (33.3-171.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 37 | 47.0 | 78.7 | (55.4-108.5) |  |  |  |  |  |  |
| Female | 32 | 48.1 | 66.6 | (45.5-94.0) |  | Female | 17 | 14.7 | 115.7 | (67.4-185.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 11.2 | nc | (nc-nc) |  | Male | 11 | 14.6 | 75.3 | (37.5-134.7) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 17 | 15.6 | 108.9 | (63.4-174.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  | Male | 152 | 144.6 | 105.1 | (89.1-123.2) |
| Female | 1 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 21.6 | 92.4 | (56.4-142.7) |  | Male | 6 | 10.0 | 60.0 | (21.9-130.6) |
| Female | 7 | 13.0 | 53.9 | (21.6-111.0) |  | Female | 8 | 6.1 | 131.2 | (56.5-258.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 6.1 | 81.9 | (26.4-191.2) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 16.6 | 114.8 | (69.1-179.2) |  | Male | 12 | 9.0 | 132.8 | (68.6-232.1) |
| Female | 13 | 12.1 | 107.3 | (57.1-183.4) |  | Female | 38 | 26.2 | 145.3 | (102.8-199.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 13.8 | 36.2 | (11.7-84.4) |  |  |  |  |  |  |
| Female | 3 | 4.6 | nc | (nc-nc) |  | Female | 31 | 36.4 | 85.1 | (57.8-120.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 44 | 77.9 | 56.5 | (41.0-75.8) |  | Male | 468 | 552.0 | 84.8 | (77.3-92.8) |
| Female | 49 | 80.1 | 61.1 | (45.2-80.8) |  | Female | 515 | 553.2 | 93.1 | (85.2-101.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

164

# Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 3.5 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 8 | 12.4 | 64.5 | (27.8-127.2) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 5 | 10.7 | 46.9 | (15.1-109.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

165

# Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 8.9 | nc | (nc-nc) |  | Male | 3 | 5.4 | nc | (nc-nc) |
| Female | 5 | 2.6 | 189.7 | (61.1-442.8) |  | Female | 8 | 3.7 | 217.1 | (93.5-427.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 5 | 4.8 | 104.6 | (33.7-244.0) |
| Female | 36 | 29.4 | 122.6 | (85.9-169.7) |  | Female | 4 | 3.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 9.4 | 74.6 | (29.9-153.7) |  |  |  |  |  |  |
| Female | 8 | 7.9 | 101.2 | (43.6-199.4) |  | Female | 4 | 2.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 44 | 30.0 | 146.7 | (106.5-196.9) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.4 | nc | (nc-nc) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 4 | 5.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 8 | 6.9 | 116.7 | (50.3-230.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 16.0 | 50.1 | (21.6-98.8) |  | Male | 106 | 112.5 | 94.3 | (77.2-114.0) |
| Female | 6 | 14.0 | 42.7 | (15.6-93.0) |  | Female | 110 | 98.4 | 111.8 | (91.9-134.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

166

# Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 9.5 | 115.3 | (57.5-206.2) |  | Male | 5 | 6.3 | 79.3 | (25.6-185.1) |
| Female | 1 | 3.5 | nc | (nc-nc) |  | Female | 2 | 5.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.6 | 89.4 | (28.8-208.7) |
| Female | 33 | 40.1 | 82.3 | (56.7-115.6) |  | Female | 5 | 4.8 | 105.2 | (33.9-245.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.6 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 10.8 | 64.6 | (25.9-133.1) |  |  |  |  |  |  |
| Female | 10 | 10.9 | 91.9 | (44.0-169.0) |  | Female | 4 | 3.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 5 | 3.3 | 152.2 | (49.0-355.2) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 6 | 3.4 | 175.5 | (64.1-382.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 33 | 34.7 | 95.1 | (65.5-133.6) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 5.4 | 111.9 | (40.9-243.5) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 4 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 7 | 7.4 | 95.1 | (38.1-196.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 13 | 8.9 | 145.5 | (77.4-248.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 17.3 | 104.2 | (61.7-164.6) |  | Male | 118 | 129.2 | 91.3 | (75.6-109.4) |
| Female | 10 | 18.3 | 54.7 | (26.2-100.6) |  | Female | 111 | 132.9 | 83.5 | (68.7-100.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

167

# Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 21.9 | 54.7 | (28.2-95.6) |  | Male | 18 | 13.2 | 136.2 | (80.7-215.3) |
| Female | 9 | 8.3 | 108.1 | (49.3-205.2) |  | Female | 14 | 10.3 | 136.2 | (74.4-228.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 10 | 11.7 | 85.1 | (40.8-156.6) |
| Female | 87 | 80.1 | 108.6 | (87.0-133.9) |  | Female | 12 | 10.5 | 114.1 | (58.9-199.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 9.0 | 55.3 | (17.8-129.1) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 1 | 4.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 23.3 | 47.3 | (23.6-84.6) |  |  |  |  |  |  |
| Female | 14 | 25.3 | 55.3 | (30.2-92.9) |  | Female | 4 | 7.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.6 | nc | (nc-nc) |  | Male | 0 | 7.3 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 3 | 8.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 70 | 72.5 | 96.6 | (75.3-122.1) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 10.7 | 93.4 | (44.7-171.9) |  | Male | 5 | 5.0 | 100.8 | (32.5-235.2) |
| Female | 4 | 6.6 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 6 | 1.7 | 348.2 | (127.2-758.0) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 8.2 | 133.6 | (66.6-239.1) |  | Male | 5 | 4.4 | 112.7 | (36.3-262.9) |
| Female | 5 | 6.3 | 79.1 | (25.5-184.6) |  | Female | 8 | 12.9 | 62.2 | (26.8-122.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 9 | 18.2 | 49.5 | (22.6-93.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 38.6 | 57.0 | (35.7-86.4) |  | Male | 223 | 274.3 | 81.3 | (71.0-92.7) |
| Female | 22 | 40.7 | 54.1 | (33.9-81.9) |  | Female | 235 | 281.8 | 83.4 | (73.1-94.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

168

# Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 85 | 80.9 | 105.1 | (83.9-129.9) |  | Male | 37 | 56.9 | 65.1 | (45.8-89.7) |
| Female | 41 | 31.4 | 130.7 | (93.8-177.4) |  | Female | 32 | 49.9 | 64.1 | (43.8-90.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 13 | 18.6 | 70.0 | (37.2-119.7) |  | Male | 19 | 16.0 | 119.1 | (71.7-185.9) |
| Female | 15 | 15.8 | 94.9 | (53.1-156.6) |  | Female | 16 | 13.4 | 119.2 | (68.1-193.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 2.6 | nc | (nc-nc) |  | Male | 57 | 50.6 | 112.6 | (85.3-145.9) |
| Female | 318 | 355.8 | 89.4 | (79.8-99.8) |  | Female | 33 | 43.5 | 75.9 | (52.3-106.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 52 | 41.0 | 126.9 | (94.8-166.5) |
| Female | 20 | 13.8 | 144.7 | (88.4-223.5) |  | Female | 12 | 18.1 | 66.3 | (34.2-115.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 101 | 93.7 | 107.8 | (87.8-131.0) |  |  |  |  |  |  |
| Female | 97 | 97.8 | 99.1 | (80.4-121.0) |  | Female | 27 | 32.8 | 82.3 | (54.2-119.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 20 | 22.5 | 89.0 | (54.4-137.5) |  | Male | 24 | 28.2 | 85.2 | (54.6-126.8) |
| Female | 5 | 6.0 | 83.3 | (26.8-194.4) |  | Female | 20 | 30.6 | 65.3 | (39.9-100.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 11 | 9.5 | 115.7 | (57.7-207.0) |  | Male | 227 | 302.9 | 74.9 | (65.5-85.4) |
| Female | 5 | 7.8 | 64.2 | (20.7-149.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 47 | 48.2 | 97.6 | (71.7-129.8) |  | Male | 23 | 19.5 | 117.7 | (74.6-176.6) |
| Female | 34 | 28.2 | 120.7 | (83.6-168.7) |  | Female | 20 | 12.3 | 162.4 | (99.2-250.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 19 | 12.5 | 151.4 | (91.1-236.5) |  | Male | 13 | 17.9 | 72.8 | (38.7-124.5) |
| Female | 8 | 4.2 | 189.5 | (81.6-373.4) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 28 | 35.8 | 78.3 | (52.0-113.1) |  | Male | 23 | 25.0 | 91.8 | (58.2-137.8) |
| Female | 43 | 27.5 | 156.2 | (113.0-210.4) |  | Female | 76 | 77.0 | 98.7 | (77.7-123.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 64 | 29.5 | 217.3 | (167.3-277.4) |  |  |  |  |  |  |
| Female | 9 | 9.6 | 93.7 | (42.8-178.0) |  | Female | 86 | 79.3 | 108.5 | (86.7-133.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 193 | 147.9 | 130.5 | (112.7-150.2) |  | Male | 1179 | 1146.8 | 102.8 | (97.0-108.8) |
| Female | 186 | 161.9 | 114.9 | (99.0-132.6) |  | Female | 1213 | 1212.7 | 100.0 | (94.5-105.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

169

# Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 34 | 25.5 | 133.2 | (92.2-186.1) |  | Male | 16 | 16.5 | 97.2 | (55.5-157.9) |
| Female | 5 | 9.5 | 52.6 | (17.0-122.8) |  | Female | 17 | 12.5 | 136.3 | (79.4-218.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 4.7 | 150.5 | (60.3-310.1) |  | Male | 2 | 4.8 | nc | (nc-nc) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 15 | 14.5 | 103.2 | (57.7-170.3) |
| Female | 89 | 96.3 | 92.4 | (74.2-113.8) |  | Female | 9 | 12.3 | 73.3 | (33.4-139.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 11.5 | 78.6 | (35.9-149.2) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 2 | 5.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 36 | 28.0 | 128.7 | (90.1-178.2) |  |  |  |  |  |  |
| Female | 27 | 28.8 | 93.7 | (61.8-136.4) |  | Female | 8 | 8.9 | 90.4 | (38.9-178.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 6.8 | nc | (nc-nc) |  | Male | 6 | 8.6 | 69.5 | (25.4-151.4) |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 10 | 9.3 | 107.4 | (51.4-197.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 84 | 89.7 | 93.7 | (74.7-116.0) |
| Female | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 13.6 | 117.6 | (67.2-191.1) |  | Male | 5 | 5.9 | 84.3 | (27.2-196.8) |
| Female | 4 | 7.8 | nc | (nc-nc) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 10.0 | 80.3 | (34.6-158.2) |  | Male | 3 | 6.3 | nc | (nc-nc) |
| Female | 6 | 7.3 | 82.3 | (30.1-179.1) |  | Female | 6 | 16.6 | 36.2 | (13.2-78.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 8.5 | 106.4 | (48.6-202.1) |  |  |  |  |  |  |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 21 | 21.8 | 96.5 | (59.7-147.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 46.1 | 60.8 | (40.4-87.9) |  | Male | 311 | 336.7 | 92.4 | (82.4-103.2) |
| Female | 35 | 48.2 | 72.6 | (50.5-100.9) |  | Female | 283 | 333.6 | 84.8 | (75.2-95.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

170

# Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 11.5 | 43.3 | (14.0-101.1) |  | Male | 5 | 7.7 | 65.0 | (21.0-151.8) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 3 | 5.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 5 | 2.3 | 220.2 | (71.0-513.8) |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 4 | 6.7 | nc | (nc-nc) |
| Female | 50 | 45.3 | 110.4 | (81.9-145.6) |  | Female | 3 | 5.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 5.7 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 13.0 | 115.2 | (64.4-190.0) |  |  |  |  |  |  |
| Female | 14 | 11.6 | 121.2 | (66.2-203.4) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 48 | 44.6 | 107.6 | (79.3-142.7) |
| Female | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 6.6 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.6 | nc | (nc-nc) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 3 | 8.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 4.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 16 | 10.5 | 152.1 | (86.9-247.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 21.4 | 112.0 | (71.7-166.7) |  | Male | 152 | 159.8 | 95.1 | (80.6-111.5) |
| Female | 13 | 20.4 | 63.7 | (33.9-109.0) |  | Female | 134 | 148.1 | 90.5 | (75.8-107.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

171

# Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 69 | 77.1 | 89.5 | (69.6-113.2) |  | Male | 42 | 52.1 | 80.6 | (58.1-109.0) |
| Female | 24 | 29.6 | 81.0 | (51.9-120.6) |  | Female | 30 | 45.4 | 66.1 | (44.6-94.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 15 | 16.4 | 91.3 | (51.0-150.5) |  | Male | 24 | 14.9 | 161.4 | (103.4-240.2) |
| Female | 17 | 14.3 | 119.0 | (69.3-190.5) |  | Female | 9 | 12.7 | 71.0 | (32.4-134.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 2.5 | nc | (nc-nc) |  | Male | 54 | 46.3 | 116.6 | (87.6-152.1) |
| Female | 323 | 331.3 | 97.5 | (87.2-108.7) |  | Female | 46 | 40.6 | 113.4 | (83.0-151.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 55 | 36.9 | 149.2 | (112.4-194.2) |
| Female | 15 | 12.4 | 120.8 | (67.5-199.2) |  | Female | 18 | 16.9 | 106.6 | (63.1-168.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 111 | 87.3 | 127.2 | (104.6-153.2) |  |  |  |  |  |  |
| Female | 113 | 91.4 | 123.6 | (101.8-148.6) |  | Female | 27 | 30.5 | 88.7 | (58.4-129.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 27 | 20.8 | 129.9 | (85.6-188.9) |  | Male | 25 | 26.4 | 94.5 | (61.2-139.6) |
| Female | 9 | 5.7 | 158.1 | (72.1-300.1) |  | Female | 25 | 28.9 | 86.6 | (56.0-127.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 7.8 | 64.4 | (20.7-150.2) |  | Male | 314 | 277.3 | 113.2 | (101.1-126.5) |
| Female | 3 | 6.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 35 | 43.6 | 80.3 | (55.9-111.7) |  | Male | 13 | 18.3 | 71.1 | (37.8-121.5) |
| Female | 26 | 26.4 | 98.6 | (64.4-144.5) |  | Female | 20 | 11.5 | 174.3 | (106.4-269.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 17 | 11.5 | 147.2 | (85.7-235.7) |  | Male | 11 | 14.1 | 77.8 | (38.8-139.2) |
| Female | 4 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 45 | 32.9 | 137.0 | (99.9-183.3) |  | Male | 12 | 21.6 | 55.6 | (28.7-97.0) |
| Female | 28 | 25.2 | 111.1 | (73.8-160.5) |  | Female | 51 | 68.2 | 74.8 | (55.7-98.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 56 | 26.9 | 208.5 | (157.5-270.7) |  |  |  |  |  |  |
| Female | 11 | 9.0 | 121.6 | (60.6-217.6) |  | Female | 70 | 74.6 | 93.8 | (73.1-118.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 205 | 139.3 | 147.2 | (127.7-168.8) |  | Male | 1229 | 1055.5 | 116.4 | (110.0-123.1) |
| Female | 179 | 153.9 | 116.3 | (99.9-134.6) |  | Female | 1156 | 1128.2 | 102.5 | (96.6-108.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

172

# Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 15.5 | 84.1 | (44.7-143.8) |  | Male | 23 | 9.6 | 239.6 | (151.8-359.5) |
| Female | 9 | 5.4 | 166.9 | (76.2-316.9) |  | Female | 12 | 7.1 | 169.1 | (87.3-295.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  | Male | 5 | 2.9 | 174.2 | (56.1-406.6) |
| Female | 5 | 2.2 | 225.6 | (72.7-526.4) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 14 | 8.5 | 165.3 | (90.3-277.4) |
| Female | 56 | 56.2 | 99.6 | (75.3-129.4) |  | Female | 12 | 7.0 | 170.8 | (88.2-298.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 6.6 | nc | (nc-nc) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 16.6 | 108.3 | (64.1-171.1) |  |  |  |  |  |  |
| Female | 22 | 16.3 | 134.7 | (84.4-203.9) |  | Female | 9 | 5.1 | 176.1 | (80.4-334.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  | Male | 7 | 5.2 | 135.0 | (54.1-278.1) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 6 | 5.3 | 113.7 | (41.5-247.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 57 | 53.0 | 107.6 | (81.5-139.4) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 7.9 | 151.7 | (78.3-265.1) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 2 | 4.5 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 4 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 5.9 | 170.1 | (81.4-312.8) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 6 | 4.2 | 144.2 | (52.7-313.9) |  | Female | 12 | 9.5 | 126.7 | (65.4-221.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 5.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 17 | 12.7 | 133.4 | (77.7-213.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 27.8 | 79.1 | (49.5-119.7) |  | Male | 211 | 198.5 | 106.3 | (92.5-121.7) |
| Female | 27 | 27.6 | 97.8 | (64.4-142.2) |  | Female | 224 | 191.9 | 116.7 | (101.9-133.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

173

# Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 40 | 51.6 | 77.5 | (55.4-105.6) |  | Male | 9 | 35.4 | 25.4 | (11.6-48.3) |
| Female | 32 | 20.3 | 158.0 | (108.0-223.0) |  | Female | 20 | 31.7 | 63.0 | (38.5-97.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 10.9 | 64.2 | (25.7-132.3) |  | Male | 5 | 10.0 | 49.9 | (16.1-116.5) |
| Female | 9 | 9.6 | 93.6 | (42.7-177.7) |  | Female | 7 | 8.7 | 80.7 | (32.3-166.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 32 | 31.2 | 102.5 | (70.1-144.7) |
| Female | 193 | 227.7 | 84.8 | (73.2-97.6) |  | Female | 20 | 27.9 | 71.8 | (43.8-110.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 24.9 | 84.4 | (52.2-129.1) |
| Female | 9 | 8.9 | 101.7 | (46.4-193.0) |  | Female | 8 | 11.6 | 69.1 | (29.8-136.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 71 | 58.6 | 121.2 | (94.6-152.9) |  |  |  |  |  |  |
| Female | 80 | 62.7 | 127.6 | (101.2-158.8) |  | Female | 19 | 20.9 | 90.9 | (54.7-141.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 20 | 14.0 | 143.1 | (87.4-221.0) |  | Male | 22 | 17.7 | 124.2 | (77.8-188.0) |
| Female | 10 | 3.9 | 256.7 | (122.9-472.1) |  | Female | 19 | 19.7 | 96.2 | (57.9-150.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 5.4 | 93.3 | (30.1-217.8) |  | Male | 135 | 186.2 | 72.5 | (60.8-85.8) |
| Female | 3 | 4.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 35 | 29.5 | 118.5 | (82.5-164.8) |  | Male | 16 | 12.3 | 130.3 | (74.4-211.5) |
| Female | 18 | 18.0 | 99.8 | (59.1-157.7) |  | Female | 6 | 7.9 | 76.3 | (27.9-166.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 11 | 7.8 | 141.4 | (70.5-253.0) |  | Male | 9 | 10.2 | 88.2 | (40.2-167.4) |
| Female | 6 | 2.7 | 219.6 | (80.2-478.0) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 23 | 21.7 | 106.0 | (67.2-159.0) |  | Male | 17 | 15.0 | 113.7 | (66.2-182.0) |
| Female | 17 | 17.0 | 99.9 | (58.2-159.9) |  | Female | 51 | 48.4 | 105.3 | (78.4-138.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 24 | 18.0 | 133.1 | (85.2-198.0) |  |  |  |  |  |  |
| Female | 8 | 6.2 | 129.6 | (55.8-255.4) |  | Female | 56 | 51.1 | 109.7 | (82.8-142.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 122 | 93.8 | 130.1 | (108.0-155.4) |  | Male | 671 | 710.1 | 94.5 | (87.5-101.9) |
| Female | 114 | 105.2 | 108.4 | (89.4-130.2) |  | Female | 778 | 775.6 | 100.3 | (93.4-107.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

174

# Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 7.5 | 67.0 | (21.6-156.3) |  | Male | 16 | 4.6 | 347.2 | (198.3-563.9) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 7 | 3.4 | 203.8 | (81.7-420.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 3 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 37 | 28.0 | 132.1 | (93.0-182.0) |  | Female | 2 | 3.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 4 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 7.9 | 75.6 | (27.6-164.5) |  |  |  |  |  |  |
| Female | 3 | 7.7 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 35 | 26.7 | 131.0 | (91.2-182.2) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 9 | 4.5 | 199.0 | (90.8-377.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 5 | 6.6 | 76.0 | (24.5-177.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 13.6 | 51.4 | (20.6-105.8) |  | Male | 100 | 96.7 | 103.4 | (84.1-125.8) |
| Female | 9 | 14.0 | 64.4 | (29.4-122.3) |  | Female | 101 | 94.3 | 107.1 | (87.3-130.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

175

# Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 16.9 | 106.7 | (63.2-168.6) |  | Male | 22 | 12.5 | 175.6 | (110.0-265.8) |
| Female | 1 | 6.0 | nc | (nc-nc) |  | Female | 18 | 10.7 | 167.7 | (99.4-265.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.2 | 120.0 | (38.7-280.1) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 8 | 3.4 | 238.2 | (102.6-469.5) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 0.6 | nc | (nc-nc) |  | Male | 12 | 11.2 | 107.5 | (55.5-187.8) |
| Female | 88 | 82.8 | 106.3 | (85.3-131.0) |  | Female | 3 | 9.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 9.7 | 113.4 | (56.5-202.9) |
| Female | 1 | 3.3 | nc | (nc-nc) |  | Female | 2 | 3.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 20.9 | 129.0 | (85.0-187.7) |  |  |  |  |  |  |
| Female | 27 | 19.8 | 136.1 | (89.7-198.1) |  | Female | 9 | 7.2 | 124.5 | (56.8-236.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 3 | 6.1 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 8 | 5.8 | 136.9 | (59.0-269.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 60 | 67.6 | 88.8 | (67.7-114.2) |
| Female | 3 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 11.1 | 117.2 | (62.3-200.4) |  | Male | 6 | 4.3 | 140.3 | (51.2-305.4) |
| Female | 8 | 6.1 | 132.0 | (56.8-260.0) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  | Male | 6 | 3.4 | 177.8 | (64.9-386.9) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 7.7 | 104.1 | (44.8-205.1) |  | Male | 15 | 5.8 | 258.7 | (144.7-426.7) |
| Female | 8 | 5.5 | 144.4 | (62.2-284.5) |  | Female | 19 | 18.0 | 105.7 | (63.6-165.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 6.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 10 | 17.9 | 55.8 | (26.7-102.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 30 | 31.3 | 95.8 | (64.6-136.7) |  | Male | 270 | 251.8 | 107.2 | (94.8-120.8) |
| Female | 41 | 32.3 | 127.0 | (91.1-172.3) |  | Female | 285 | 261.5 | 109.0 | (96.7-122.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

176

# Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 25.5 | 78.6 | (48.0-121.4) |  | Male | 40 | 16.0 | 249.2 | (178.0-339.4) |
| Female | 13 | 9.1 | 142.1 | (75.6-243.0) |  | Female | 24 | 12.6 | 190.8 | (122.2-283.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.5 | nc | (nc-nc) |  | Male | 7 | 4.8 | 145.4 | (58.3-299.6) |
| Female | 6 | 3.9 | 152.8 | (55.8-332.6) |  | Female | 7 | 3.9 | 177.9 | (71.3-366.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 16 | 14.1 | 113.2 | (64.7-183.8) |
| Female | 128 | 101.2 | 126.5 | (105.5-150.4) |  | Female | 15 | 12.2 | 122.5 | (68.5-202.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 11.5 | 104.0 | (53.7-181.6) |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 5 | 5.2 | 96.8 | (31.2-226.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 27.7 | 93.9 | (61.3-137.6) |  |  |  |  |  |  |
| Female | 18 | 27.6 | 65.2 | (38.6-103.0) |  | Female | 10 | 9.2 | 109.1 | (52.2-200.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 6.9 | nc | (nc-nc) |  | Male | 13 | 8.7 | 149.4 | (79.5-255.5) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 12 | 8.9 | 135.0 | (69.7-235.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 103 | 93.8 | 109.8 | (89.6-133.2) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 13.6 | 81.0 | (40.4-144.9) |  | Male | 6 | 5.9 | 101.4 | (37.0-220.7) |
| Female | 7 | 8.0 | 87.6 | (35.1-180.5) |  | Female | 2 | 3.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.8 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 9.8 | 153.8 | (86.0-253.6) |  | Male | 8 | 5.8 | 138.2 | (59.5-272.4) |
| Female | 9 | 7.1 | 126.3 | (57.6-239.8) |  | Female | 17 | 17.3 | 98.4 | (57.3-157.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 8.6 | 58.3 | (18.8-136.0) |  |  |  |  |  |  |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 16 | 23.6 | 67.8 | (38.7-110.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 46.4 | 73.3 | (50.8-102.5) |  | Male | 357 | 337.2 | 105.9 | (95.2-117.4) |
| Female | 43 | 48.1 | 89.4 | (64.7-120.4) |  | Female | 377 | 338.5 | 111.4 | (100.4-123.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

177

# Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 7.4 | 95.2 | (38.1-196.2) |  | Male | 5 | 4.4 | 112.6 | (36.3-262.7) |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 2 | 3.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 3.9 | 205.1 | (88.3-404.1) |
| Female | 33 | 26.7 | 123.6 | (85.0-173.6) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 7.8 | 64.3 | (20.7-150.1) |  |  |  |  |  |  |
| Female | 8 | 8.2 | 97.6 | (42.0-192.3) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 28 | 25.0 | 112.1 | (74.5-162.1) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 2.7 | 294.3 | (126.7-579.8) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 5 | 4.2 | 120.3 | (38.8-280.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 5 | 6.2 | 80.8 | (26.1-188.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 13.1 | nc | (nc-nc) |  | Male | 91 | 92.7 | 98.2 | (79.0-120.5) |
| Female | 17 | 13.9 | 122.2 | (71.2-195.7) |  | Female | 98 | 93.6 | 104.7 | (85.0-127.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

178

# Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 34 | 35.6 | 95.6 | (66.2-133.6) |  | Male | 22 | 24.4 | 90.3 | (56.6-136.8) |
| Female | 11 | 14.1 | 78.3 | (39.0-140.0) |  | Female | 16 | 20.7 | 77.2 | (44.1-125.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 7.4 | 94.1 | (37.7-194.0) |  | Male | 8 | 6.9 | 115.3 | (49.6-227.2) |
| Female | 5 | 6.4 | 78.7 | (25.4-183.6) |  | Female | 6 | 6.0 | 100.8 | (36.8-219.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 22 | 21.5 | 102.2 | (64.0-154.7) |
| Female | 137 | 153.1 | 89.5 | (75.1-105.8) |  | Female | 17 | 18.9 | 90.0 | (52.4-144.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 17.4 | 91.7 | (52.4-149.0) |
| Female | 9 | 5.7 | 158.0 | (72.1-300.0) |  | Female | 15 | 7.8 | 191.9 | (107.3-316.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 47 | 40.8 | 115.2 | (84.7-153.2) |  |  |  |  |  |  |
| Female | 58 | 43.6 | 133.1 | (101.1-172.1) |  | Female | 16 | 14.0 | 114.4 | (65.4-185.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 9.7 | 123.5 | (63.8-215.8) |  | Male | 9 | 12.3 | 73.3 | (33.4-139.1) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 11 | 13.7 | 80.0 | (39.9-143.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 3.5 | 173.1 | (63.2-376.8) |  | Male | 128 | 129.8 | 98.6 | (82.3-117.3) |
| Female | 2 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 30 | 20.6 | 146.0 | (98.5-208.4) |  | Male | 9 | 8.5 | 105.6 | (48.2-200.5) |
| Female | 9 | 12.2 | 74.1 | (33.8-140.6) |  | Female | 5 | 5.5 | 90.7 | (29.2-211.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 5.4 | 111.0 | (40.5-241.7) |  | Male | 5 | 6.4 | 78.4 | (25.3-182.9) |
| Female | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 14.9 | 127.7 | (76.8-199.4) |  | Male | 9 | 10.2 | 88.0 | (40.1-167.0) |
| Female | 11 | 11.6 | 94.8 | (47.2-169.6) |  | Female | 40 | 30.6 | 130.8 | (93.4-178.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 12.6 | 103.4 | (55.0-176.8) |  |  |  |  |  |  |
| Female | 6 | 4.2 | 143.4 | (52.4-312.1) |  | Female | 37 | 33.9 | 109.1 | (76.8-150.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 51 | 64.6 | 79.0 | (58.8-103.9) |  | Male | 493 | 491.0 | 100.4 | (91.7-109.7) |
| Female | 67 | 71.3 | 93.9 | (72.8-119.3) |  | Female | 533 | 522.5 | 102.0 | (93.5-111.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

179

# Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 26.6 | 86.4 | (54.8-129.7) |  | Male | 39 | 18.0 | 217.0 | (154.3-296.7) |
| Female | 12 | 9.3 | 129.4 | (66.8-226.0) |  | Female | 27 | 14.1 | 191.1 | (125.9-278.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 5.3 | 132.0 | (52.9-271.9) |  | Male | 7 | 5.3 | 132.2 | (53.0-272.3) |
| Female | 7 | 4.4 | 158.4 | (63.5-326.5) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 11 | 15.7 | 69.8 | (34.8-125.0) |
| Female | 142 | 113.1 | 125.6 | (105.8-148.0) |  | Female | 11 | 13.0 | 84.5 | (42.1-151.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 13.5 | 74.0 | (35.4-136.1) |
| Female | 5 | 3.9 | 127.4 | (41.1-297.3) |  | Female | 5 | 5.6 | 89.7 | (28.9-209.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 34 | 30.3 | 112.2 | (77.7-156.8) |  |  |  |  |  |  |
| Female | 32 | 28.2 | 113.4 | (77.5-160.1) |  | Female | 12 | 10.1 | 118.6 | (61.2-207.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 7.7 | nc | (nc-nc) |  | Male | 13 | 9.4 | 138.7 | (73.8-237.2) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 7 | 8.9 | 78.5 | (31.4-161.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.1 | nc | (nc-nc) |  | Male | 122 | 106.8 | 114.2 | (94.9-136.4) |
| Female | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 25 | 15.7 | 159.1 | (103.0-234.9) |  | Male | 4 | 6.4 | nc | (nc-nc) |
| Female | 6 | 8.7 | 68.9 | (25.2-150.0) |  | Female | 4 | 3.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 4.3 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 10.7 | 83.8 | (38.3-159.1) |  | Male | 7 | 7.2 | 97.3 | (39.0-200.4) |
| Female | 3 | 7.6 | nc | (nc-nc) |  | Female | 26 | 21.0 | 123.9 | (80.9-181.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 9.9 | 101.1 | (48.4-185.9) |  |  |  |  |  |  |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 27 | 26.4 | 102.4 | (67.5-149.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 49 | 50.0 | 98.0 | (72.5-129.6) |  | Male | 403 | 376.1 | 107.2 | (97.0-118.2) |
| Female | 69 | 50.9 | 135.6 | (105.5-171.6) |  | Female | 431 | 368.0 | 117.1 | (106.3-128.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

180

# Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 31 | 22.7 | 136.3 | (92.6-193.4) |  | Male | 22 | 13.4 | 164.4 | (103.0-248.9) |
| Female | 9 | 8.3 | 108.7 | (49.6-206.4) |  | Female | 15 | 10.1 | 148.0 | (82.8-244.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  | Male | 6 | 4.1 | 146.8 | (53.6-319.6) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 2 | 3.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 17 | 11.7 | 144.9 | (84.4-232.1) |
| Female | 86 | 80.3 | 107.1 | (85.7-132.3) |  | Female | 14 | 10.5 | 133.4 | (72.9-223.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 8.7 | 149.9 | (79.8-256.4) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 5 | 4.3 | 117.3 | (37.8-273.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 23.1 | 82.1 | (49.4-128.3) |  |  |  |  |  |  |
| Female | 28 | 24.0 | 116.6 | (77.5-168.5) |  | Female | 9 | 7.4 | 121.7 | (55.5-231.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 5.7 | 105.7 | (38.6-230.2) |  | Male | 8 | 7.4 | 108.0 | (46.5-212.8) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 8 | 8.0 | 99.8 | (43.0-196.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 82 | 73.9 | 110.9 | (88.2-137.7) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 10.7 | 103.1 | (51.4-184.5) |  | Male | 5 | 5.0 | 99.5 | (32.1-232.2) |
| Female | 8 | 6.7 | 118.7 | (51.1-234.0) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.1 | nc | (nc-nc) |  | Male | 4 | 1.7 | nc | (nc-nc) |
| Female | 4 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 8.1 | 85.9 | (34.4-177.1) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 10 | 6.1 | 164.9 | (78.9-303.2) |  | Female | 11 | 12.5 | 88.3 | (44.0-158.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 6.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 14 | 18.7 | 74.7 | (40.8-125.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 31 | 40.8 | 75.9 | (51.6-107.8) |  | Male | 297 | 278.3 | 106.7 | (94.9-119.6) |
| Female | 59 | 43.6 | 135.3 | (103.0-174.6) |  | Female | 310 | 281.7 | 110.0 | (98.1-123.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

181

# Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 9.2 | 119.1 | (59.4-213.2) |  | Male | 6 | 5.7 | 105.9 | (38.7-230.6) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 6 | 4.0 | 149.8 | (54.7-326.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 5.0 | nc | (nc-nc) |
| Female | 38 | 32.5 | 116.8 | (82.6-160.3) |  | Female | 5 | 4.0 | 124.6 | (40.2-290.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 4.0 | 276.7 | (137.9-495.1) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 9.8 | 61.1 | (22.3-133.1) |  |  |  |  |  |  |
| Female | 11 | 8.9 | 123.1 | (61.4-220.4) |  | Female | 5 | 3.0 | 168.8 | (54.4-393.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 46 | 33.1 | 139.2 | (101.9-185.6) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.7 | nc | (nc-nc) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 5 | 5.3 | 94.4 | (30.4-220.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 11 | 7.7 | 143.2 | (71.4-256.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 16.7 | 89.6 | (50.1-147.9) |  | Male | 128 | 119.3 | 107.3 | (89.5-127.5) |
| Female | 12 | 16.3 | 73.7 | (38.1-128.8) |  | Female | 113 | 109.9 | 102.8 | (84.8-123.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

182

# Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 9.9 | 101.2 | (48.4-186.1) |  | Male | 4 | 6.7 | nc | (nc-nc) |
| Female | 1 | 3.8 | nc | (nc-nc) |  | Female | 7 | 5.8 | 121.2 | (48.6-249.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 5.9 | 118.1 | (47.3-243.3) |
| Female | 46 | 44.4 | 103.7 | (75.9-138.3) |  | Female | 3 | 5.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 4.9 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 11.3 | 176.3 | (107.6-272.3) |  |  |  |  |  |  |
| Female | 18 | 11.7 | 154.0 | (91.2-243.5) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 36 | 37.3 | 96.6 | (67.6-133.7) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.8 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 5 | 3.4 | 144.9 | (46.7-338.2) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.1 | nc | (nc-nc) |  | Male | 4 | 2.8 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 10 | 8.7 | 114.9 | (55.0-211.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 8 | 10.0 | 79.7 | (34.3-157.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 18.2 | 66.1 | (34.1-115.5) |  | Male | 132 | 137.4 | 96.1 | (80.4-114.0) |
| Female | 20 | 19.9 | 100.3 | (61.2-154.9) |  | Female | 150 | 146.9 | 102.1 | (86.4-119.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

183

# Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 11.6 | 77.5 | (35.3-147.0) |  | Male | 9 | 7.9 | 113.4 | (51.8-215.4) |
| Female | 6 | 4.0 | 150.2 | (54.8-326.9) |  | Female | 9 | 6.2 | 144.9 | (66.1-275.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 5 | 2.3 | 215.0 | (69.3-501.7) |
| Female | 4 | 2.0 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 6 | 7.0 | 85.2 | (31.1-185.5) |
| Female | 49 | 50.1 | 97.8 | (72.3-129.3) |  | Female | 3 | 5.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 6.0 | 116.1 | (46.5-239.2) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 13.6 | 132.0 | (78.2-208.7) |  |  |  |  |  |  |
| Female | 16 | 12.6 | 126.5 | (72.3-205.5) |  | Female | 5 | 4.4 | 112.5 | (36.2-262.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 3.3 | nc | (nc-nc) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 3.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 60 | 44.9 | 133.7 | (102.0-172.1) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 6.9 | 86.7 | (31.7-188.7) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 4.8 | 124.7 | (45.5-271.5) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 7 | 3.4 | 207.0 | (82.9-426.6) |  | Female | 9 | 9.5 | 95.0 | (43.4-180.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 4.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 10 | 11.2 | 88.9 | (42.6-163.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 21.5 | 55.9 | (28.8-97.6) |  | Male | 164 | 163.6 | 100.2 | (85.5-116.8) |
| Female | 12 | 21.3 | 56.2 | (29.0-98.2) |  | Female | 150 | 161.1 | 93.1 | (78.8-109.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

184

# Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 65 | 60.4 | 107.6 | (83.0-137.1) |  | Male | 29 | 38.4 | 75.6 | (50.6-108.6) |
| Female | 22 | 24.3 | 90.7 | (56.8-137.3) |  | Female | 23 | 33.3 | 69.1 | (43.8-103.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 14 | 11.0 | 127.8 | (69.8-214.4) |  | Male | 8 | 11.1 | 72.1 | (31.0-142.0) |
| Female | 11 | 10.1 | 109.0 | (54.3-195.0) |  | Female | 12 | 10.1 | 118.8 | (61.3-207.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 29 | 34.0 | 85.3 | (57.1-122.4) |
| Female | 235 | 240.1 | 97.9 | (85.8-111.2) |  | Female | 22 | 31.5 | 69.9 | (43.8-105.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 36 | 25.5 | 141.0 | (98.7-195.2) |
| Female | 9 | 8.5 | 105.3 | (48.1-199.9) |  | Female | 13 | 12.8 | 101.7 | (54.1-174.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 75 | 65.2 | 115.1 | (90.5-144.3) |  |  |  |  |  |  |
| Female | 81 | 73.7 | 109.8 | (87.2-136.5) |  | Female | 27 | 22.4 | 120.3 | (79.2-175.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 15.2 | 78.8 | (40.7-137.6) |  | Male | 19 | 20.0 | 94.9 | (57.1-148.2) |
| Female | 5 | 4.6 | 108.5 | (35.0-253.3) |  | Female | 11 | 23.8 | 46.2 | (23.0-82.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 5.2 | 116.1 | (42.4-252.6) |  | Male | 157 | 196.2 | 80.0 | (68.0-93.6) |
| Female | 4 | 4.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 31 | 30.6 | 101.3 | (68.8-143.8) |  | Male | 14 | 13.8 | 101.3 | (55.3-170.0) |
| Female | 25 | 19.8 | 126.5 | (81.8-186.7) |  | Female | 10 | 9.4 | 106.6 | (51.0-196.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 13 | 8.4 | 155.6 | (82.7-266.0) |  | Male | 11 | 9.4 | 116.5 | (58.1-208.5) |
| Female | 2 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 26 | 23.8 | 109.3 | (71.4-160.1) |  | Male | 9 | 14.5 | 62.1 | (28.3-117.9) |
| Female | 25 | 19.1 | 130.9 | (84.7-193.3) |  | Female | 47 | 46.0 | 102.1 | (75.0-135.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 17 | 19.0 | 89.4 | (52.0-143.1) |  |  |  |  |  |  |
| Female | 8 | 7.0 | 114.1 | (49.1-224.8) |  | Female | 60 | 53.8 | 111.4 | (85.0-143.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 110 | 106.3 | 103.5 | (85.0-124.7) |  | Male | 741 | 771.8 | 96.0 | (89.2-103.2) |
| Female | 124 | 121.4 | 102.1 | (84.9-121.8) |  | Female | 852 | 850.3 | 100.2 | (93.6-107.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

185

# Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 10.9 | 137.2 | (76.7-226.3) |  | Male | 6 | 7.7 | 77.4 | (28.3-168.6) |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 4 | 6.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 13 | 6.9 | 188.8 | (100.4-322.9) |
| Female | 47 | 51.6 | 91.1 | (66.9-121.1) |  | Female | 7 | 5.9 | 119.2 | (47.7-245.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 5.9 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 13.1 | 145.3 | (87.5-227.0) |  |  |  |  |  |  |
| Female | 14 | 13.4 | 104.1 | (56.9-174.7) |  | Female | 7 | 4.6 | 153.2 | (61.4-315.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 3.2 | 221.8 | (88.9-457.1) |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 44 | 42.8 | 102.9 | (74.8-138.1) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 6.8 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 0 | 3.9 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 4.7 | nc | (nc-nc) |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 12 | 10.2 | 117.6 | (60.7-205.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 8 | 11.3 | 70.7 | (30.4-139.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 20.3 | 93.7 | (56.4-146.4) |  | Male | 164 | 157.6 | 104.1 | (88.7-121.3) |
| Female | 28 | 21.9 | 128.1 | (85.1-185.2) |  | Female | 152 | 167.6 | 90.7 | (76.9-106.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

186

# Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 29.9 | 80.3 | (51.5-119.5) |  | Male | 23 | 19.3 | 119.0 | (75.4-178.5) |
| Female | 17 | 12.3 | 138.6 | (80.7-222.0) |  | Female | 19 | 16.7 | 113.8 | (68.5-177.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 5.5 | 180.6 | (86.4-332.1) |  | Male | 4 | 5.7 | nc | (nc-nc) |
| Female | 7 | 5.2 | 135.7 | (54.4-279.6) |  | Female | 2 | 5.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 22 | 17.0 | 129.1 | (80.9-195.5) |
| Female | 132 | 127.0 | 104.0 | (87.0-123.3) |  | Female | 16 | 16.1 | 99.5 | (56.9-161.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 13.6 | 125.0 | (72.8-200.1) |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 5 | 6.6 | 75.5 | (24.3-176.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 44 | 32.9 | 133.7 | (97.1-179.5) |  |  |  |  |  |  |
| Female | 34 | 37.3 | 91.1 | (63.1-127.3) |  | Female | 13 | 11.6 | 111.7 | (59.4-191.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 8.0 | 125.5 | (60.1-230.8) |  | Male | 11 | 10.2 | 108.3 | (54.0-193.7) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 16 | 12.0 | 133.2 | (76.1-216.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  | Male | 95 | 106.3 | 89.4 | (72.3-109.3) |
| Female | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 16.1 | 99.2 | (56.6-161.1) |  | Male | 6 | 7.0 | 86.1 | (31.4-187.3) |
| Female | 9 | 10.3 | 87.7 | (40.0-166.5) |  | Female | 5 | 4.7 | 106.0 | (34.2-247.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 4.4 | 227.7 | (109.0-418.8) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 11.8 | 169.6 | (103.6-262.0) |  | Male | 12 | 7.4 | 162.7 | (84.0-284.3) |
| Female | 6 | 9.7 | 62.2 | (22.7-135.3) |  | Female | 27 | 23.1 | 117.0 | (77.1-170.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 10.0 | 49.9 | (16.1-116.5) |  |  |  |  |  |  |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 32 | 28.8 | 111.3 | (76.1-157.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 54 | 53.9 | 100.2 | (75.3-130.7) |  | Male | 418 | 396.3 | 105.5 | (95.6-116.1) |
| Female | 50 | 62.2 | 80.4 | (59.7-106.1) |  | Female | 431 | 438.3 | 98.3 | (89.3-108.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

187

# Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 5.4 | nc | (nc-nc) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 24 | 23.2 | 103.2 | (66.1-153.6) |  | Female | 7 | 2.5 | 277.5 | (111.2-571.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 6.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 5.5 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 27 | 22.1 | 122.2 | (80.5-177.8) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 5 | 5.2 | 96.4 | (31.1-224.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 10.2 | nc | (nc-nc) |  | Male | 60 | 79.1 | 75.9 | (57.9-97.7) |
| Female | 7 | 9.5 | 73.8 | (29.6-152.1) |  | Female | 71 | 73.3 | 96.9 | (75.6-122.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

188

# Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 6.7 | 74.9 | (24.2-174.9) |  | Male | 5 | 4.5 | 111.4 | (35.9-259.9) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 5 | 3.6 | 139.3 | (44.9-325.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 1 | 3.9 | nc | (nc-nc) |
| Female | 24 | 28.8 | 83.3 | (53.4-124.0) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 7.6 | 105.0 | (45.2-207.0) |  |  |  |  |  |  |
| Female | 6 | 7.4 | 81.5 | (29.8-177.3) |  | Female | 5 | 2.6 | 195.8 | (63.1-456.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 25 | 25.5 | 97.9 | (63.3-144.5) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 3 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 3 | 5.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 4 | 6.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 12.4 | 113.0 | (61.7-189.5) |  | Male | 88 | 92.7 | 95.0 | (76.2-117.0) |
| Female | 16 | 12.8 | 124.8 | (71.3-202.7) |  | Female | 86 | 93.6 | 91.9 | (73.5-113.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

189

# Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 54 | 47.7 | 113.2 | (85.0-147.7) |  | Male | 25 | 31.1 | 80.4 | (52.0-118.8) |
| Female | 25 | 18.9 | 132.1 | (85.5-195.0) |  | Female | 27 | 26.8 | 100.8 | (66.4-146.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 9.2 | 87.0 | (37.5-171.5) |  | Male | 11 | 9.0 | 121.7 | (60.7-217.7) |
| Female | 9 | 8.3 | 108.0 | (49.3-205.0) |  | Female | 5 | 8.0 | 62.5 | (20.1-145.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 27 | 27.6 | 97.8 | (64.4-142.3) |
| Female | 197 | 201.1 | 98.0 | (84.8-112.6) |  | Female | 27 | 25.2 | 107.3 | (70.7-156.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 21.9 | 82.1 | (48.7-129.8) |
| Female | 8 | 7.2 | 111.8 | (48.1-220.2) |  | Female | 8 | 10.4 | 76.9 | (33.1-151.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 56 | 53.1 | 105.4 | (79.6-136.9) |  |  |  |  |  |  |
| Female | 52 | 58.4 | 89.1 | (66.5-116.8) |  | Female | 10 | 18.5 | 54.2 | (25.9-99.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 12.6 | 95.1 | (49.1-166.1) |  | Male | 19 | 16.2 | 117.2 | (70.5-183.0) |
| Female | 1 | 3.6 | nc | (nc-nc) |  | Female | 17 | 18.6 | 91.5 | (53.3-146.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 4.0 | nc | (nc-nc) |  | Male | 186 | 166.9 | 111.4 | (96.0-128.7) |
| Female | 3 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 25.8 | 104.8 | (69.0-152.4) |  | Male | 13 | 11.2 | 116.3 | (61.9-198.9) |
| Female | 16 | 16.1 | 99.5 | (56.9-161.7) |  | Female | 7 | 7.4 | 94.9 | (38.0-195.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 7.0 | 114.9 | (49.5-226.3) |  | Male | 11 | 6.7 | 163.0 | (81.3-291.7) |
| Female | 3 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 21 | 19.3 | 108.7 | (67.3-166.2) |  | Male | 14 | 12.1 | 115.8 | (63.2-194.3) |
| Female | 16 | 15.3 | 104.4 | (59.6-169.5) |  | Female | 34 | 38.2 | 89.1 | (61.7-124.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 16.1 | 93.1 | (52.1-153.5) |  |  |  |  |  |  |
| Female | 4 | 5.6 | nc | (nc-nc) |  | Female | 48 | 45.1 | 106.5 | (78.5-141.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 98 | 85.2 | 115.0 | (93.4-140.2) |  | Male | 663 | 633.7 | 104.6 | (96.8-112.9) |
| Female | 113 | 95.6 | 118.1 | (97.4-142.0) |  | Female | 699 | 690.2 | 101.3 | (93.9-109.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

190

# Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 34 | 25.7 | 132.2 | (91.6-184.8) |  | Male | 19 | 16.8 | 113.3 | (68.2-177.0) |
| Female | 15 | 8.9 | 168.4 | (94.2-277.8) |  | Female | 14 | 13.0 | 107.3 | (58.6-180.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.9 | 123.4 | (45.1-268.7) |  | Male | 5 | 4.9 | 101.5 | (32.7-236.8) |
| Female | 4 | 4.1 | nc | (nc-nc) |  | Female | 5 | 3.8 | 130.1 | (41.9-303.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 17 | 14.8 | 115.2 | (67.1-184.4) |
| Female | 110 | 101.0 | 108.9 | (89.5-131.3) |  | Female | 9 | 12.2 | 74.1 | (33.8-140.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 12.0 | 66.8 | (28.8-131.7) |
| Female | 7 | 3.5 | 197.6 | (79.2-407.1) |  | Female | 9 | 5.1 | 176.8 | (80.7-335.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 41 | 28.4 | 144.3 | (103.5-195.8) |  |  |  |  |  |  |
| Female | 31 | 26.9 | 115.1 | (78.2-163.3) |  | Female | 14 | 9.2 | 153.0 | (83.6-256.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 7.0 | 114.0 | (49.1-224.5) |  | Male | 12 | 8.8 | 135.9 | (70.1-237.4) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 6 | 8.6 | 69.4 | (25.3-151.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 106 | 95.3 | 111.2 | (91.1-134.5) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 14.2 | 98.5 | (53.8-165.2) |  | Male | 6 | 6.0 | 99.4 | (36.3-216.4) |
| Female | 1 | 8.0 | nc | (nc-nc) |  | Female | 0 | 3.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.9 | nc | (nc-nc) |  | Male | 6 | 3.2 | 185.3 | (67.7-403.4) |
| Female | 3 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 10.2 | 147.0 | (82.2-242.5) |  | Male | 6 | 6.5 | 92.8 | (33.9-202.0) |
| Female | 14 | 7.2 | 194.8 | (106.4-326.8) |  | Female | 20 | 18.9 | 105.9 | (64.6-163.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 8.8 | 148.4 | (79.0-253.8) |  |  |  |  |  |  |
| Female | 8 | 2.7 | 291.3 | (125.4-574.1) |  | Female | 30 | 23.3 | 128.7 | (86.8-183.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 45 | 47.1 | 95.5 | (69.7-127.8) |  | Male | 391 | 347.2 | 112.6 | (101.7-124.3) |
| Female | 67 | 47.4 | 141.3 | (109.5-179.4) |  | Female | 396 | 338.0 | 117.2 | (105.9-129.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

191

# Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 9 | 10.0 | 89.9 | (41.0-170.7) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 7 | 7.6 | 92.6 | (37.1-190.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

192

# Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 9.6 | 167.3 | (95.5-271.6) |  | Male | 8 | 6.5 | 122.3 | (52.7-241.1) |
| Female | 6 | 3.2 | 189.7 | (69.3-412.9) |  | Female | 6 | 4.5 | 133.7 | (48.8-291.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 5 | 1.9 | 267.0 | (86.0-623.0) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 10 | 5.8 | 172.6 | (82.6-317.4) |
| Female | 36 | 35.9 | 100.4 | (70.3-139.0) |  | Female | 5 | 4.3 | 117.2 | (37.8-273.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 4.7 | 107.1 | (34.5-249.9) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 10.9 | 100.5 | (50.1-179.9) |  |  |  |  |  |  |
| Female | 10 | 9.6 | 104.0 | (49.8-191.3) |  | Female | 0 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 45 | 34.6 | 130.0 | (94.8-173.9) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 5.5 | nc | (nc-nc) |  | Male | 4 | 2.3 | nc | (nc-nc) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 4 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 3.9 | 127.2 | (41.0-296.8) |  | Male | 4 | 2.8 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 3 | 6.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 6 | 8.0 | 74.8 | (27.3-162.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 17.4 | 91.8 | (52.4-149.0) |  | Male | 161 | 131.5 | 122.4 | (104.2-142.9) |
| Female | 20 | 16.9 | 118.1 | (72.1-182.4) |  | Female | 120 | 119.1 | 100.8 | (83.6-120.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

193

# Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 48 | 28.2 | 170.2 | (125.5-225.7) |  | Male | 10 | 18.7 | 53.3 | (25.5-98.1) |
| Female | 13 | 10.1 | 128.4 | (68.3-219.5) |  | Female | 15 | 15.0 | 100.3 | (56.1-165.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 5.6 | nc | (nc-nc) |  | Male | 7 | 5.4 | 129.3 | (51.8-266.5) |
| Female | 0 | 4.6 | nc | (nc-nc) |  | Female | 7 | 4.3 | 161.9 | (64.9-333.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 18 | 16.6 | 108.2 | (64.1-171.0) |
| Female | 87 | 112.3 | 77.5 | (62.0-95.5) |  | Female | 17 | 13.7 | 123.9 | (72.1-198.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 13.3 | 97.5 | (51.8-166.7) |
| Female | 2 | 4.1 | nc | (nc-nc) |  | Female | 10 | 5.7 | 174.7 | (83.6-321.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 31.8 | 78.7 | (50.9-116.2) |  |  |  |  |  |  |
| Female | 29 | 31.4 | 92.4 | (61.9-132.8) |  | Female | 9 | 10.2 | 87.9 | (40.1-166.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 7.6 | 132.0 | (63.2-242.7) |  | Male | 11 | 9.6 | 114.0 | (56.8-204.0) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 6 | 9.9 | 60.5 | (22.1-131.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 7 | 2.5 | 280.4 | (112.3-577.7) |  | Male | 107 | 101.2 | 105.8 | (86.7-127.8) |
| Female | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 15.7 | 108.2 | (63.0-173.3) |  | Male | 13 | 6.7 | 194.7 | (103.6-333.0) |
| Female | 11 | 8.9 | 124.0 | (61.8-221.9) |  | Female | 1 | 3.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.2 | nc | (nc-nc) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 11.6 | 103.9 | (53.6-181.4) |  | Male | 4 | 7.5 | nc | (nc-nc) |
| Female | 11 | 8.4 | 131.3 | (65.5-235.0) |  | Female | 19 | 22.0 | 86.5 | (52.0-135.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 9.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 25 | 25.3 | 99.0 | (64.0-146.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 49 | 50.6 | 96.8 | (71.6-128.0) |  | Male | 390 | 381.3 | 102.3 | (92.4-112.9) |
| Female | 60 | 51.9 | 115.6 | (88.2-148.8) |  | Female | 358 | 380.4 | 94.1 | (84.6-104.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

194

# Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 15.2 | 92.0 | (50.2-154.3) |  | Male | 4 | 9.9 | nc | (nc-nc) |
| Female | 8 | 5.7 | 141.0 | (60.7-277.8) |  | Female | 4 | 7.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 5 | 2.4 | 207.8 | (67.0-484.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 14 | 8.7 | 160.9 | (87.9-270.0) |
| Female | 56 | 60.4 | 92.7 | (70.0-120.4) |  | Female | 5 | 7.5 | 66.4 | (21.4-154.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 6.9 | 115.3 | (49.6-227.1) |
| Female | 5 | 2.1 | 238.5 | (76.9-556.5) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 16.7 | 59.8 | (28.6-109.9) |  |  |  |  |  |  |
| Female | 14 | 17.2 | 81.2 | (44.4-136.3) |  | Female | 7 | 5.5 | 127.0 | (50.9-261.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 4.1 | 172.0 | (68.9-354.4) |  | Male | 6 | 5.2 | 116.2 | (42.4-253.0) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 10 | 5.5 | 180.7 | (86.5-332.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 60 | 54.2 | 110.7 | (84.5-142.5) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 8.3 | 169.4 | (92.5-284.3) |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 8 | 4.9 | 164.8 | (70.9-324.7) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.0 | 83.9 | (27.0-195.8) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 7 | 4.5 | 156.0 | (62.5-321.5) |  | Female | 10 | 11.1 | 90.3 | (43.2-166.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 5.1 | 97.8 | (31.5-228.2) |  |  |  |  |  |  |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 12 | 13.7 | 87.6 | (45.2-153.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 44 | 27.7 | 159.0 | (115.5-213.4) |  | Male | 228 | 202.1 | 112.8 | (98.6-128.4) |
| Female | 32 | 29.4 | 108.9 | (74.5-153.7) |  | Female | 208 | 206.6 | 100.7 | (87.5-115.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

195

# Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 7.9 | 152.9 | (78.9-267.0) |  | Male | 7 | 5.4 | 129.2 | (51.8-266.3) |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 5 | 4.3 | 116.8 | (37.6-272.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 4.8 | 104.9 | (33.8-244.8) |
| Female | 36 | 33.9 | 106.1 | (74.3-146.9) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 4.1 | 146.1 | (53.3-317.9) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 9.1 | 110.0 | (52.7-202.3) |  |  |  |  |  |  |
| Female | 13 | 8.3 | 156.3 | (83.1-267.2) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 4 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 39 | 31.3 | 124.5 | (88.5-170.1) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 4.7 | 147.5 | (59.1-304.0) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 4 | 2.2 | nc | (nc-nc) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 13 | 6.6 | 197.2 | (104.9-337.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 5 | 7.8 | 64.2 | (20.7-149.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 14.7 | 95.4 | (52.1-160.1) |  | Male | 133 | 112.0 | 118.7 | (99.4-140.7) |
| Female | 13 | 14.8 | 88.1 | (46.8-150.6) |  | Female | 114 | 109.4 | 104.2 | (85.9-125.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

196

# Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 2.2 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 7 | 11.2 | 62.5 | (25.0-128.8) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 10 | 9.0 | 110.8 | (53.1-203.8) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 4.1 | nc | (nc-nc) |  | Male | 32 | 33.2 | 96.3 | (65.8-135.9) |
| Female | 8 | 4.6 | 175.3 | (75.5-345.4) |  | Female | 28 | 35.9 | 77.9 | (51.8-112.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

197

# Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 30.2 | 66.3 | (40.5-102.4) |  | Male | 34 | 19.0 | 179.4 | (124.2-250.7) |
| Female | 4 | 12.3 | nc | (nc-nc) |  | Female | 23 | 16.1 | 142.5 | (90.3-213.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 5.5 | 91.6 | (29.5-213.7) |  | Male | 8 | 5.6 | 142.0 | (61.1-279.8) |
| Female | 6 | 5.1 | 117.6 | (43.0-256.0) |  | Female | 8 | 5.1 | 155.7 | (67.1-306.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 12 | 16.9 | 71.0 | (36.7-124.1) |
| Female | 112 | 124.4 | 90.0 | (74.1-108.3) |  | Female | 12 | 15.9 | 75.5 | (39.0-131.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 13.3 | 75.4 | (36.1-138.6) |
| Female | 6 | 4.1 | 146.5 | (53.5-318.8) |  | Female | 5 | 6.6 | 76.2 | (24.6-177.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 32.9 | 73.0 | (46.8-108.7) |  |  |  |  |  |  |
| Female | 44 | 37.4 | 117.7 | (85.5-158.1) |  | Female | 14 | 11.5 | 121.9 | (66.6-204.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 7.8 | nc | (nc-nc) |  | Male | 7 | 10.1 | 69.1 | (27.7-142.3) |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 13 | 12.0 | 108.2 | (57.5-185.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  | Male | 122 | 103.2 | 118.2 | (98.1-141.1) |
| Female | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 15.6 | 90.0 | (49.2-151.0) |  | Male | 1 | 7.0 | nc | (nc-nc) |
| Female | 12 | 10.1 | 118.8 | (61.3-207.5) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 4.3 | nc | (nc-nc) |  | Male | 5 | 3.4 | 149.0 | (48.0-347.7) |
| Female | 0 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 11.9 | 92.4 | (46.1-165.4) |  | Male | 7 | 6.9 | 101.2 | (40.6-208.6) |
| Female | 11 | 9.6 | 114.4 | (57.0-204.6) |  | Female | 35 | 21.6 | 161.8 | (112.7-225.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 10.0 | 50.2 | (16.2-117.2) |  |  |  |  |  |  |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 31 | 28.2 | 110.1 | (74.8-156.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 53.5 | 59.8 | (40.9-84.5) |  | Male | 351 | 390.9 | 89.8 | (80.7-99.7) |
| Female | 45 | 61.6 | 73.1 | (53.3-97.8) |  | Female | 416 | 431.5 | 96.4 | (87.4-106.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

198

# Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 2.1 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

199

# Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 8.9 | 78.3 | (31.4-161.3) |  | Male | 8 | 6.1 | 130.3 | (56.1-256.8) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 1 | 4.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 5.4 | nc | (nc-nc) |
| Female | 45 | 37.8 | 118.9 | (86.7-159.1) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 10.4 | 96.0 | (46.0-176.6) |  |  |  |  |  |  |
| Female | 7 | 9.6 | 72.9 | (29.2-150.1) |  | Female | 2 | 3.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 5 | 3.2 | 157.6 | (50.8-367.8) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 31 | 36.4 | 85.2 | (57.9-121.0) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 5.4 | 148.4 | (63.9-292.4) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 3.6 | 137.9 | (44.5-321.9) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 2 | 7.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 3.4 | 146.4 | (47.2-341.6) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 8 | 8.7 | 91.8 | (39.5-180.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 16.7 | 101.6 | (59.2-162.7) |  | Male | 122 | 128.1 | 95.3 | (79.1-113.7) |
| Female | 11 | 16.6 | 66.1 | (33.0-118.3) |  | Female | 105 | 123.1 | 85.3 | (69.7-103.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

200

# Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 10.1 | 79.0 | (34.0-155.7) |  | Male | 7 | 6.5 | 107.2 | (43.0-220.9) |
| Female | 7 | 3.9 | 180.9 | (72.5-372.8) |  | Female | 2 | 5.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 5.7 | nc | (nc-nc) |
| Female | 41 | 39.7 | 103.3 | (74.1-140.2) |  | Female | 3 | 5.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 4.6 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 11.1 | 81.0 | (36.9-153.7) |  |  |  |  |  |  |
| Female | 15 | 11.7 | 128.2 | (71.7-211.4) |  | Female | 5 | 3.7 | 136.4 | (43.9-318.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 30 | 36.1 | 83.0 | (56.0-118.5) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 5.4 | 110.7 | (40.4-241.0) |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.0 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 3 | 7.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 11 | 9.1 | 120.6 | (60.1-215.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 18.3 | 87.2 | (49.8-141.7) |  | Male | 110 | 134.3 | 81.9 | (67.3-98.7) |
| Female | 15 | 19.7 | 76.0 | (42.5-125.4) |  | Female | 121 | 137.4 | 88.1 | (73.1-105.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

201

# Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 2 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 2 | 5.6 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 6.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  | Male | 10 | 22.5 | 44.4 | (21.2-81.6) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 10 | 18.8 | 53.1 | (25.4-97.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

202

# Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 8 | 4.2 | 188.6 | (81.2-371.7) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 18 | 14.7 | 122.1 | (72.3-193.0) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 8 | 12.1 | 65.9 | (28.4-129.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

203

# Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

204

# Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 5.7 | 87.0 | (28.0-203.1) |  | Male | 12 | 3.5 | 345.7 | (178.4-603.9) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 18 | 19.7 | 91.2 | (54.0-144.1) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.4 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 6.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 5.8 | 119.8 | (48.0-246.9) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 20 | 20.2 | 99.0 | (60.4-152.9) |
| Female | 2 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 2.9 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 10.3 | 68.0 | (27.2-140.1) |  | Male | 71 | 73.2 | 97.0 | (75.8-122.4) |
| Female | 5 | 9.7 | 51.4 | (16.6-119.8) |  | Female | 62 | 67.6 | 91.7 | (70.3-117.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

205

# Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 10.1 | 69.5 | (27.8-143.1) |  | Male | 26 | 7.0 | 372.7 | (243.4-546.1) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 18 | 5.3 | 341.9 | (202.5-540.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 3 | 6.1 | nc | (nc-nc) |
| Female | 55 | 39.5 | 139.3 | (104.9-181.3) |  | Female | 5 | 4.7 | 107.1 | (34.5-249.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 5.0 | 158.7 | (68.3-312.6) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 4 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 11.5 | 112.8 | (60.0-192.8) |  |  |  |  |  |  |
| Female | 11 | 10.4 | 105.8 | (52.7-189.2) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 5 | 3.5 | 142.2 | (45.8-331.9) |
| Female | 4 | 0.6 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.0 | nc | (nc-nc) |  | Male | 47 | 38.4 | 122.4 | (90.0-162.8) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 6.0 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 3.1 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 4.2 | 191.5 | (82.5-377.4) |  | Male | 5 | 2.9 | 169.6 | (54.7-395.9) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 9 | 8.0 | 112.1 | (51.1-212.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 11 | 9.0 | 122.9 | (61.2-219.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 18.6 | 80.6 | (45.1-133.0) |  | Male | 173 | 141.4 | 122.3 | (104.8-142.0) |
| Female | 12 | 17.7 | 67.7 | (34.9-118.2) |  | Female | 154 | 131.5 | 117.2 | (99.4-137.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

206

# Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 39 | 35.1 | 111.2 | (79.1-152.0) |  | Male | 21 | 22.9 | 91.6 | (56.7-140.0) |
| Female | 11 | 13.2 | 83.6 | (41.7-149.6) |  | Female | 21 | 19.1 | 109.9 | (68.0-168.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 13 | 6.7 | 193.7 | (103.0-331.3) |  | Male | 7 | 6.7 | 104.7 | (42.0-215.8) |
| Female | 10 | 5.9 | 170.2 | (81.5-313.1) |  | Female | 6 | 5.6 | 106.9 | (39.0-232.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.1 | nc | (nc-nc) |  | Male | 17 | 20.3 | 83.9 | (48.8-134.3) |
| Female | 159 | 146.1 | 108.8 | (92.6-127.1) |  | Female | 15 | 17.7 | 84.6 | (47.3-139.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 16.2 | 98.8 | (56.4-160.5) |
| Female | 1 | 5.2 | nc | (nc-nc) |  | Female | 10 | 7.4 | 135.2 | (64.7-248.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 47 | 39.1 | 120.2 | (88.3-159.9) |  |  |  |  |  |  |
| Female | 31 | 40.4 | 76.8 | (52.2-109.0) |  | Female | 21 | 13.2 | 158.7 | (98.2-242.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 9.3 | 118.0 | (58.8-211.1) |  | Male | 13 | 11.9 | 109.0 | (58.0-186.4) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 7 | 12.8 | 54.6 | (21.9-112.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  | Male | 121 | 123.2 | 98.2 | (81.5-117.3) |
| Female | 3 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 19.1 | 83.7 | (47.8-135.9) |  | Male | 10 | 8.2 | 121.5 | (58.2-223.4) |
| Female | 9 | 11.6 | 77.8 | (35.5-147.8) |  | Female | 2 | 5.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  | Male | 3 | 4.6 | nc | (nc-nc) |
| Female | 5 | 1.8 | 282.4 | (91.0-658.9) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 14.1 | 85.1 | (43.9-148.6) |  | Male | 15 | 8.9 | 169.1 | (94.6-278.9) |
| Female | 9 | 10.7 | 84.3 | (38.5-160.1) |  | Female | 24 | 27.8 | 86.4 | (55.4-128.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 11.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 29 | 32.9 | 88.2 | (59.1-126.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 52 | 63.0 | 82.5 | (61.6-108.2) |  | Male | 477 | 466.5 | 102.2 | (93.3-111.9) |
| Female | 73 | 68.4 | 106.7 | (83.6-134.1) |  | Female | 492 | 492.5 | 99.9 | (91.3-109.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

207

# Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 40 | 35.5 | 112.6 | (80.4-153.3) |  | Male | 34 | 22.0 | 154.6 | (107.1-216.1) |
| Female | 10 | 13.4 | 74.7 | (35.8-137.4) |  | Female | 18 | 17.3 | 104.2 | (61.7-164.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 6.2 | 128.7 | (55.4-253.7) |  | Male | 8 | 6.5 | 122.2 | (52.6-240.8) |
| Female | 9 | 5.5 | 163.9 | (74.8-311.2) |  | Female | 5 | 5.6 | 89.5 | (28.9-209.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 26 | 19.6 | 132.7 | (86.7-194.5) |
| Female | 153 | 134.8 | 113.5 | (96.2-133.0) |  | Female | 16 | 17.2 | 93.0 | (53.1-151.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 15.2 | 85.4 | (45.4-146.1) |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 6 | 7.1 | 84.8 | (31.0-184.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 38.5 | 75.2 | (50.4-108.1) |  |  |  |  |  |  |
| Female | 33 | 41.1 | 80.2 | (55.2-112.7) |  | Female | 12 | 12.4 | 97.1 | (50.1-169.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 9.1 | 77.2 | (30.9-159.1) |  | Male | 11 | 11.8 | 92.8 | (46.3-166.1) |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 17 | 13.2 | 128.5 | (74.8-205.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 156 | 117.6 | 132.7 | (112.7-155.2) |
| Female | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 17.9 | 78.0 | (42.6-130.9) |  | Male | 7 | 8.1 | 85.9 | (34.4-177.1) |
| Female | 10 | 10.9 | 91.7 | (43.9-168.6) |  | Female | 2 | 5.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 5.0 | 100.9 | (32.5-235.4) |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 13.8 | 50.6 | (20.3-104.3) |  | Male | 9 | 7.8 | 115.5 | (52.7-219.3) |
| Female | 15 | 10.5 | 142.4 | (79.6-234.8) |  | Female | 39 | 22.8 | 171.0 | (121.6-233.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 11.4 | 44.0 | (14.2-102.6) |  |  |  |  |  |  |
| Female | 1 | 3.9 | nc | (nc-nc) |  | Female | 29 | 30.2 | 96.1 | (64.3-138.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 41 | 62.4 | 65.7 | (47.2-89.2) |  | Male | 455 | 451.5 | 100.8 | (91.7-110.5) |
| Female | 40 | 65.9 | 60.7 | (43.3-82.6) |  | Female | 465 | 466.7 | 99.6 | (90.8-109.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

208

# New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 5 | 3.6 | 139.8 | (45.1-326.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

209

# New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 110 | 96.8 | 113.6 | (93.4-136.9) |  | Male | 33 | 61.9 | 53.3 | (36.7-74.9) |
| Female | 38 | 39.7 | 95.6 | (67.7-131.3) |  | Female | 23 | 53.8 | 42.8 | (27.1-64.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 16 | 18.3 | 87.5 | (50.0-142.1) |  | Male | 20 | 18.0 | 111.2 | (67.9-171.7) |
| Female | 21 | 16.9 | 124.5 | (77.0-190.3) |  | Female | 14 | 16.5 | 84.6 | (46.2-142.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 51 | 55.0 | 92.7 | (69.0-121.9) |
| Female | 339 | 392.8 | 86.3 | (77.4-96.0) |  | Female | 36 | 51.4 | 70.0 | (49.0-96.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 59 | 42.2 | 139.9 | (106.5-180.5) |
| Female | 24 | 13.7 | 174.8 | (111.9-260.0) |  | Female | 30 | 20.9 | 143.4 | (96.7-204.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 119 | 105.3 | 113.0 | (93.6-135.2) |  |  |  |  |  |  |
| Female | 107 | 120.9 | 88.5 | (72.5-106.9) |  | Female | 37 | 36.7 | 100.8 | (71.0-139.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 34 | 24.9 | 136.3 | (94.4-190.5) |  | Male | 36 | 32.4 | 111.1 | (77.8-153.8) |
| Female | 9 | 7.5 | 119.7 | (54.6-227.3) |  | Female | 63 | 39.1 | 161.1 | (123.8-206.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 9 | 8.2 | 110.3 | (50.3-209.5) |  | Male | 379 | 326.2 | 116.2 | (104.8-128.5) |
| Female | 4 | 7.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 71 | 50.4 | 140.9 | (110.1-177.8) |  | Male | 37 | 22.3 | 165.8 | (116.7-228.5) |
| Female | 46 | 32.4 | 142.0 | (104.0-189.5) |  | Female | 27 | 15.4 | 175.1 | (115.4-254.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 21 | 13.7 | 153.1 | (94.8-234.1) |  | Male | 8 | 14.3 | 56.0 | (24.1-110.3) |
| Female | 14 | 4.8 | 288.9 | (157.8-484.7) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 37 | 39.0 | 95.0 | (66.9-130.9) |  | Male | 20 | 23.5 | 85.1 | (51.9-131.4) |
| Female | 23 | 31.8 | 72.3 | (45.8-108.5) |  | Female | 74 | 73.5 | 100.6 | (79.0-126.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 69 | 31.3 | 220.3 | (171.4-278.9) |  |  |  |  |  |  |
| Female | 11 | 11.5 | 95.7 | (47.7-171.2) |  | Female | 93 | 88.3 | 105.4 | (85.0-129.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 244 | 171.9 | 141.9 | (124.7-160.9) |  | Male | 1477 | 1258.4 | 117.4 | (111.5-123.5) |
| Female | 199 | 197.6 | 100.7 | (87.2-115.7) |  | Female | 1365 | 1389.3 | 98.2 | (93.1-103.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

210

# New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 11 | 14.0 | 78.7 | (39.3-140.9) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 12 | 13.7 | 87.6 | (45.2-153.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

211

# New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 10 | 7.7 | 129.4 | (62.0-238.0) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 9.3 | 54.0 | (17.4-126.1) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 4.5 | nc | (nc-nc) |  | Male | 18 | 32.1 | 56.1 | (33.2-88.7) |
| Female | 2 | 3.8 | nc | (nc-nc) |  | Female | 23 | 26.1 | 88.1 | (55.8-132.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

212

# New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 5.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 4 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 11 | 17.1 | 64.5 | (32.1-115.3) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 10 | 13.8 | 72.3 | (34.6-133.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

213